---
title: "12 Health Care Stocks Moving In Thursday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300731335.md"
description: "During Thursday's after-market session, several healthcare stocks experienced significant price movements. Gainers included Elutia (up 17.2%), Intelligent Bio Solutions (up 9.7%), and Sunshine Biopharma (up 9.07%). Conversely, losers featured Lucid Diagnostics (down 5.5%), AgomAb Therapeutics (down 5.45%), and Kala Bio (down 4.32%). The report highlights specific percentage changes and market capitalizations for these listed companies."
datetime: "2026-10-01T21:06:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300731335.md)
  - [en](https://longbridge.com/en/news/300731335.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300731335.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Thursday's After-Market Session

### Gainers

-   **Elutia** (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million.
-   **Intelligent Bio Solutions** (NASDAQ:INBS) stock increased by 9.7% to $1.85. The company's market cap stands at $5.5 million.
-   **Sunshine Biopharma** (NASDAQ:SBFM) stock moved upwards by 9.07% to $0.75. The market value of their outstanding shares is at $2.9 million.
-   **NewGenIvf Group** (NASDAQ:NIVF) shares moved upwards by 8.9% to $0.11.
-   **NextCure** (NASDAQ:NXTC) shares moved upwards by 6.85% to $5.3. The company's market cap stands at $22.9 million.
-   **Edesa Biotech** (NASDAQ:EDSA) shares increased by 5.81% to $4.24. The market value of their outstanding shares is at $40.5 million.

### Losers

-   **Lucid Diagnostics** (NASDAQ:LUCD) stock decreased by 5.5% to $0.6 during Thursday's after-market session. The market value of their outstanding shares is at $143.4 million.
-   **AgomAb Therapeutics** (NASDAQ:AGMB) stock declined by 5.45% to $8.16. The market value of their outstanding shares is at $546.6 million.
-   **Kala Bio** (NASDAQ:KALA) stock decreased by 4.32% to $0.4. The market value of their outstanding shares is at $8.3 million.
-   **Vicore Pharma Holding** (NASDAQ:VCRE) stock declined by 3.93% to $9.06. The market value of their outstanding shares is at $267.8 million.
-   **Azitra** (AMEX:AZTR) stock decreased by 3.9% to $0.12. The market value of their outstanding shares is at $8.3 million.
-   **Imunon** (NASDAQ:IMNN) stock fell 3.79% to $1.27. The company's market cap stands at $7.2 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [AGMB.US](https://longbridge.com/en/quote/AGMB.US.md)
- [AZTR.US](https://longbridge.com/en/quote/AZTR.US.md)
- [EDSA.US](https://longbridge.com/en/quote/EDSA.US.md)
- [ELUT.US](https://longbridge.com/en/quote/ELUT.US.md)
- [IMNN.US](https://longbridge.com/en/quote/IMNN.US.md)
- [INBS.US](https://longbridge.com/en/quote/INBS.US.md)
- [KALA.US](https://longbridge.com/en/quote/KALA.US.md)
- [LUCD.US](https://longbridge.com/en/quote/LUCD.US.md)
- [NIVF.US](https://longbridge.com/en/quote/NIVF.US.md)
- [NXTC.US](https://longbridge.com/en/quote/NXTC.US.md)
- [SBFM.US](https://longbridge.com/en/quote/SBFM.US.md)
- [VCRE.US](https://longbridge.com/en/quote/VCRE.US.md)

## Related News & Research

- [Sunshine Biopharma issues Series D warrants in $6 million public offering](https://longbridge.com/en/news/301423195.md)
- [Imunon CEO Stacy Lindborg joins Maxim Growth Summit oncology panel](https://longbridge.com/en/news/301281868.md)
- [Agomab Therapeutics director David R. Epstein buys 5,000 common shares for $44,500](https://longbridge.com/en/news/301396814.md)
- [Insider Move: AgomAb Therapeutics Director Makes a Bold New Bet](https://longbridge.com/en/news/301452995.md)
- [AgomAb CEO Tim Jasper Knotnerus buys $94,880 of common shares](https://longbridge.com/en/news/301141755.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**